

# Technical Data Sheet

## InVivoMAb anti-human/rat HER2 (neu)



[bioxcell.com](http://bioxcell.com)

**Attention:** Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at <https://bioxcell.com/terms-and-conditions>.

### Lot Specific Information

Lot Number: Lot Specific\*  
Volume: Lot Specific\*  
Concentration: Lot Specific\* (generally 4 to 11 mg/ml) \*  
Total Protein: Lot Specific\*

\*This information will be noted on the certificate of analysis that ships with this product.

Product Website Link: <https://bioxcell.com/invivomab-anti-human-rat-her2-neu-be0277>

### Product Information

Catalog Number: BE0277  
Clone: 7.16.4  
Isotype: Mouse IgG2a,  $\kappa$   
Recommended Isotype Control(s): InVivoMAb mouse IgG2a isotype control, unknown specificity  
Recommended Dilution Buffer: InVivoPure pH 7.0 Dilution Buffer  
Immunogen: neu-transfected NIH 3T3 cells  
Reported Applications: *in vivo* HER2/neu inhibition  
*in vitro* HER2/neu inhibition  
Immunoprecipitation  
Immunofluorescence  
Flow cytometry  
Formulation: PBS, pH 7.0  
Contains no stabilizers or preservatives  
Endotoxin:  $\leq 1$  EU/mg ( $\leq 0.001$  EU/ $\mu$ g)  
Determined by LAL assay  
Purity:  $\geq 95\%$   
Determined by SDS-PAGE  
Sterility: 0.2  $\mu$ m filtration  
Production: Purified from cell culture supernatant in an animal-free facility  
Purification: Protein G  
RRID: [AB\\_2687800](https://abnova.com/AB_2687800)  
Molecular Weight: 150 kDa

### Description

The 7.16.4 monoclonal antibody reacts with human and rat HER2 (human epidermal growth factor receptor 2) also known as neu peptide, CD340, ErbB-2, and p185. HER2 is a 185 kDa transmembrane, receptor-like glycoprotein with intrinsic tyrosine kinase activity that is part of several cell surface receptor complexes. HER2 lacks an identified ligand however, the kinase can be activated in the absence of a ligand when overexpressed. HER2 is a proto-oncoprotein that is commonly overexpressed on a variety of different tumors. Approximately 40% of human breast cancers overexpress HER2. HER2 overexpression is associated with poorer overall survival rates, shorter times to disease progression, and increased resistance to chemotherapy. Because of these clinical characteristics anti-HER2 monoclonal antibody therapy is now a standard for the treatment of advanced breast cancers that overexpress HER2. The 7.16.4 antibody has been shown to inhibit the growth of HER2-overexpressing tumors both *in vitro* and *in vivo*.

### Storage

Store at the stock concentration at 4°C . **Do not freeze.**

It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at <https://bioxcell.com/faqs>.

## Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

## Application References

For a complete list of references, visit [https://bioxcell.com/invivomab-anti-human-rat-her2-neu-be0277?utm\\_source=cr9k1b#tab\\_references](https://bioxcell.com/invivomab-anti-human-rat-her2-neu-be0277?utm_source=cr9k1b#tab_references) or scan the QR code below.



---

**Bio X Cell, LLC**

<https://bioxcell.com>

+1-866-787-3444

[customerservice@bioxcell.com](mailto:customerservice@bioxcell.com)

*Conditions: For research use only. Not for use in diagnostic or therapeutic procedures.*

*Not for resale.*

**Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © Bio X Cell, LLC**